OCGN trade ideas
If $OCGN finds support at current price, could quickly move up$OCGN would have to create a support level where it’s at. Once everyone agrees that’s a fair price, it may try to climb to the last resistance level at $22-25. But it may retrace back down to confirm support where it’s at...
$OCGN Ocugen hopiumWith the overnight share issue at a premium of 7.65 (up from 5.25) and pre-market on 8/2/21 at 8.9 the hopium on the higher time frames may not seem so far fetched. Ocugen may be the dark horse to win the Covid-19 vaccine race.
$OCGN Making a Fast Recovery$OCGN just passed the 236 fib and if it attempts a 618 retrace that'll get a 60% gain. If it tries to shoot for previous support lines in 2019, that'll be a 100% gain from current price.
OCGN (END WEEK BIG PLAYERS)2-5-2021 This stock started selling high volume at end of trading session. Large orders of 2+ million began coming in. "Thats not your aunt Helen's money".
Bought at 5.22 ; sold 1/2 positon @ 5.91 and 6.16. The stock then went on to trade up to 8.61 in after hours.
I expect the price to be very volitile in early morning trading on Monday.
My average cost on remaining shares is 4.22. I don't expect it to drop below the closing price of 5.25. This is a risky venture (buying on such a large advance) but I took the trade for these 3 reasons:
1. High volume at end of trading day on Friday when most are usually trying to close positions. This is what NVAX did on Thursday 1/28/2021. Sensing a similar path.
2. Looked like institutions really wanted this stock based on volume and large orders of over 2 million.
3. Catylst .. Covid Vaccine that might be safe for children.
I usually dont chase a stock but this one was irresistable.
This is not trading advice. Make your own trading decisions based on your research.
This is for educational purposes so I am open to any comments on this trade.
OCGN - how to play the COVAXIN news !OCGN:
What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative.
Ok lets talk shop – technical:
POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason.
Volume: average volume is 63M, last 2 days trading above 100M.
50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal)
4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions….
Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal.
The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high
Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+.
Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !!
FDGT will wait for a pullback before entering as the trend doesn’t look healthy
This is not a recommendation of any sort
Trader safe and be safe – we are the traders union and we trade by our own rules!
OCGNFrom entry, took longer then excpected but the jump finally came. 100% gain from the 2.71 call entry.
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market.
Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market.
Ocugen and Bharat Biotech to share US commercialization profits.
Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US.
COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients.
COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape.
today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market.
Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market .
B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits.
In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program.
H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market.
Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements.
Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday.
Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
$OCGNBull flag
4hr and daily hidden bullish divergence on the RSI and MACD
Stop = Under candle wick of last touch of support
1st Target = High of previous rally
2nd Target = 1.618 fib extension
OCGN could have another runAccording to Elliot Wave Thoery, we could see a another potential run on OCGN.
$OCGN PT 6-12 and higherOcugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
either big upside or downside I bought this after hours for $1.94 for 38 shares. bounced off the VWAP and can break through the top resistance. if it does we will see big upside. if not well i loose my money. good luck happy trading don't do it like that
oh boy I just bought this after hours in hopes of the triangle breaking. don't invest like this kids
